Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 0.04M
CLLS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Cellectis S.A.NASDAQ: CLLS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$17.83M, compared with -$18.13M a year earlier. Trailing-twelve-month net income was -$67.29M.
Context
- Net income amounted to 92.7% of revenue in FY2025, up 4.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$121.46M (-79.7%) for the fiscal year ending Dec 2026, a step up from the -83.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.83M+32.3% QoQ
- Last fiscal yearDec 2025
- -$67.59M-83.9% YoY
- LTMMar 2026
- -$67.29M-11.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.6% | -11.6% | -13.2 pp |
| 1 year | -83.9% | -79.7% | +4.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (67.59M) USD
- Year-over-year change
- -83.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.59M) | -83.9% |
| FY2024 | 2024-12-31 | (36.76M) | +63.6% |
| FY2023 | 2023-12-31 | (101.06M) | +4.8% |
| FY2022 | 2022-12-31 | (106.14M) | +7.1% |
| FY2021 | 2021-12-31 | (114.2M) | — |
Net Income vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.2% is the 4th highest of 10, against a peer median of -27.1%.
- Net income amounts to 98.8% of revenue for CLLS, versus a peer median of 2954.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$27.37M USD | +52.6% | — | — | |
| LTM Mar 2026 | -$33.61M USD | +61.8% | — | 15.6% | |
| LTM Mar 2026 | -$35.7M USD | +24.2% | — | 7139.7% | |
| LTM Mar 2026 | -$56.88M USD | -75.2% | — | — | |
| LTM Mar 2026 | -CHF 66.22M CHF | -27.1% | — | 1788.8% | |
| LTM Mar 2026 | -$67.29M USD | -11.2% | — | 98.8% | |
| LTM Mar 2026 | -$74.31M USD | -17.6% | — | — | |
| LTM Mar 2026 | -$85.17M USD | — | — | 9243.0% | |
| LTM Mar 2026 | -$113.5M USD | -29.8% | — | 2954.1% | |
| LTM Mar 2026 | -$166.01M USD | -74.3% | — | — | |
| LTM Mar 2026 | -$167.85M USD | -47.7% | — | — | |
| Peer median (excluding CLLS) | — | -27.1% | — | 2954.1% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.35M | 19.17M | 755K | 41.51M | 72.95M |
| Cost of Revenue | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M |
| Gross Profit | 28.5M | 10.69M | (6.66M) | 32.32M | 63.15M |
| Gross Margin | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| Research & Development | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M |
| Selling, General & Admin | 22.88M | 8.9M | 8.12M | 8.42M | 8.6M |
| Operating Expenses | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.85M | 20.06M |
| EBITDA | (78.43M) | (76.38M) | (92.64M) | (9.46M) | (39.85M) |
| EBITDA Margin | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% |
| Operating Income | (103.48M) | (89.67M) | (97.3M) | (59.55M) | (33.08M) |
| Operating Margin | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% |
| Interest Income | 719K | 1.12M | 3.61M | 11.28M | 9.5M |
| Interest Expense | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M |
| Other Income / Expenses | 6.73M | (8.94M) | (19.16M) | 22.79M | (34.94M) |
| Income Before Tax | (96.75M) | (98.6M) | (116.46M) | (36.76M) | (68.02M) |
| Pre-Tax Margin | -318.8% | -514.3% | -15425.7% | -88.6% | -93.2% |
| Income Tax Expense | (3K) | 87K | 371K | 0 | (423K) |
| Net Income | (114.2M) | (106.14M) | (101.06M) | (36.76M) | (67.59M) |
| Net Margin | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (Basic) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| EPS (Diluted) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| Weighted Avg Shares | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
| Weighted Avg Shares (Diluted) | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.